ARTELO BIOSCIENCES, INC.
About ARTELO BIOSCIENCES, INC.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$12.9M
- Total assets
- $2.8M
- Market cap
- $4.8M
Source: SEC EDGAR · updated Jun 7, 2026
- Market cap
- $4.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 13, 2015
Market data by Polygon.io · prices are 15-minute delayed
No reviews yet. Be the first to review ARTELO BIOSCIENCES, INC..